EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION AV DETTA PRESSMEDDELANDE SKULLE VARA OTILLÅTEN, KRÄVA REGISTRERING ELLER ANNAN ÅTGÄRD ENLIGT TILLÄMPLIG LAG. VÄNLIGEN SE ”VIKTIG INFORMATION” I SLUTET AV PRESSMEDDELANDET.
The Board of Directors of SynAct Pharma AB (“SynAct” or the “Company”) has, subject to subsequent approval by the general meeting, decided, and received a proposal from a major shareholder, on a capital raise of approximately 65 MSEK (the “Capital Raise”), divided into directed issues in tranches and a rights issue. The directed issues consist of:
- A share issue to certain investors amounting to approximately 44 MSEK (the “Directed Issue 1”).
- A share issue to board members amounting to approximately 0.6 MSEK (the “Directed Issue 2”).
- A share issue to management of the Company amounting to approximately 0.5 MSEK (the “Directed Issue 3,” and together with the Directed Issue 1 and Directed Issue 2, the “Directed Issues”).